AN2 Therapeutics, Inc.
ANTXNASDAQHealthcare● Active
$3.85
+$0.03(+0.79%)
Market Cap$105497792
P/E Ratio—
52W High$6.91
52W Low$1
AN2 Therapeutics, Inc. (ANTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ANTX · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 11, 2026EPS Actual
-$0.29
Est. -$0.23 · -26.1%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 11, 2026
After Market Close
▼ Miss EPS
ANTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 11, 2026 | -$0.23 | — | — | — | — | — |
| ▼ Q2 FY2026 | May 11, 2026 | -$0.23 | -$0.29 | -26.1% | — | — | — |
| ▼ Q1 FY2026 | Mar 17, 2026 | -$0.24 | -$0.29 | -20.8% | — | — | — |
| ▼ Q4 FY2025 | Nov 12, 2025 | -$0.23 | -$0.31 | -34.8% | — | — | — |
| ▲ Q3 FY2025 | Aug 12, 2025 | -$0.31 | -$0.21 | +32.3% | — | — | — |
| ▼ Q2 FY2025 | May 13, 2025 | -$0.26 | -$0.35 | -34.6% | — | — | — |
| — Q1 FY2025 | Mar 25, 2025 | -$0.25 | -$0.25 | +0.0% | — | — | — |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.37 | -$0.43 | -16.2% | — | — | — |
Q3 FY2026
Aug 11, 2026
EPS Actual
—
EPS Est.
-$0.23
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 11, 2026Miss
EPS Actual
-$0.29
EPS Est.
-$0.23
EPS Surpr.
-26.1%
Revenue
—
Q1 FY2026
Mar 17, 2026Miss
EPS Actual
-$0.29
EPS Est.
-$0.24
EPS Surpr.
-20.8%
Revenue
—
Q4 FY2025
Nov 12, 2025Miss
EPS Actual
-$0.31
EPS Est.
-$0.23
EPS Surpr.
-34.8%
Revenue
—
Q3 FY2025
Aug 12, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.31
EPS Surpr.
+32.3%
Revenue
—
Q2 FY2025
May 13, 2025Miss
EPS Actual
-$0.35
EPS Est.
-$0.26
EPS Surpr.
-34.6%
Revenue
—
Q1 FY2025
Mar 25, 2025
EPS Actual
-$0.25
EPS Est.
-$0.25
EPS Surpr.
+0.0%
Revenue
—
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.43
EPS Est.
-$0.37
EPS Surpr.
-16.2%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.25 | $-0.25 | $-0.25 | 1 |
| Q3 FY2026 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q2 FY2026 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q1 FY2026 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Q4 FY2025 | $-0.24 | $-0.24 | $-0.24 | 1 |
| Q3 FY2025 | $-0.22 | $-0.22 | $-0.22 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 11, 2026 | -26.1% | $4.46 | $4.72 | +5.83% |
| ▼ Q1 FY2026 | Mar 17, 2026 | -20.8% | $4.69 | $5.00 | +6.61% |
| ▼ Q4 FY2025 | Nov 12, 2025 | -34.8% | $1.20 | $1.18 | -1.67% |
| ▲ Q3 FY2025 | Aug 12, 2025 | +32.3% | $1.05 | $1.05 | +0.00% |
| ▼ Q2 FY2025 | May 13, 2025 | -34.6% | $1.19 | $1.18 | -0.84% |
| ▲ Q1 FY2025 | Mar 25, 2025 | +0.0% | $1.51 | $1.50 | -0.66% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -16.2% | $1.06 | $1.01 | -4.72% |
| ▲ Q3 FY2024 | Aug 13, 2024 | +23.8% | $1.03 | $1.09 | +5.83% |
Q2 FY2026+5.83%
Report Date
May 11, 2026
EPS Beat/Miss
-26.1%
Price Before
$4.46
Price After
$4.72
Q1 FY2026+6.61%
Report Date
Mar 17, 2026
EPS Beat/Miss
-20.8%
Price Before
$4.69
Price After
$5.00
Q4 FY2025-1.67%
Report Date
Nov 12, 2025
EPS Beat/Miss
-34.8%
Price Before
$1.20
Price After
$1.18
Q3 FY2025+0.00%
Report Date
Aug 12, 2025
EPS Beat/Miss
+32.3%
Price Before
$1.05
Price After
$1.05
Q2 FY2025-0.84%
Report Date
May 13, 2025
EPS Beat/Miss
-34.6%
Price Before
$1.19
Price After
$1.18
Q1 FY2025-0.66%
Report Date
Mar 25, 2025
EPS Beat/Miss
+0.0%
Price Before
$1.51
Price After
$1.50
Q4 FY2024-4.72%
Report Date
Nov 13, 2024
EPS Beat/Miss
-16.2%
Price Before
$1.06
Price After
$1.01
Q3 FY2024+5.83%
Report Date
Aug 13, 2024
EPS Beat/Miss
+23.8%
Price Before
$1.03
Price After
$1.09
Avg Beat Reaction+1.72%
Avg Miss Reaction+1.04%
Beat Rate3 / 8 quarters
Largest Move+6.61% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ANTX ends December
AN2 Therapeutics, Inc. (ANTX) most recently reported earnings on May 11, 2026 for Q2 FY2026, posting EPS of $-0.29 — missing the analyst consensus of $-0.23 by -26.1%. The next ANTX earnings date is expected around September 1, 2026.
Each quarter, investors track ANTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ANTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ANTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ANTX earnings · 5 questionsAN2 Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ANTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ANTX historically reports after market close (AMC).
ANTX earnings datewhen is ANTX earningsANTX next earnings datewhen does ANTX report earningsANTX earnings calendar
▸ Source: FMP · AN2 Therapeutics, Inc. SEC filings · US GAAP · AN2 Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026